Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 8,700 shares, a decline of 91.8% from the March 15th total of 105,600 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 3,830,000 shares, the days-to-cover ratio is presently 0.0 days.

Adial Pharmaceuticals Stock Up 27.9 %

Shares of NASDAQ ADIL opened at $2.98 on Friday. Adial Pharmaceuticals has a twelve month low of $0.76 and a twelve month high of $14.00. The company has a market cap of $4.96 million, a PE ratio of -0.52 and a beta of 1.48. The business’s 50 day moving average price is $1.52 and its two-hundred day moving average price is $1.85.

Institutional Investors Weigh In On Adial Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ADIL. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in shares of Adial Pharmaceuticals during the first quarter worth approximately $70,000. Renaissance Technologies LLC bought a new stake in shares of Adial Pharmaceuticals during the first quarter worth approximately $40,000. Virtu Financial LLC bought a new stake in shares of Adial Pharmaceuticals in the second quarter valued at approximately $43,000. Millennium Management LLC bought a new stake in shares of Adial Pharmaceuticals in the second quarter valued at approximately $53,000. Finally, Citadel Advisors LLC boosted its stake in shares of Adial Pharmaceuticals by 1,156.2% in the third quarter. Citadel Advisors LLC now owns 265,062 shares of the company’s stock valued at $93,000 after buying an additional 243,962 shares during the period. Institutional investors own 16.41% of the company’s stock.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.